Wikipedia
CimaVax-EGF is the first therapeutic cancer vaccine developed to target non-small-cell lung carcinoma (NSCLC), the most common form of lung cancer. The vaccine was the result of a 25-year research project at Cuba’s Center of Molecular Immunology. The product has gone through 2 trial phases in Cuba and is currently in the process of going through a third trial, and there are agreements in place to test it in the United States (at Roswell Park Cancer Institute, subject to approval of an Investigational New Drug by the U.S. Food and Drug Administration), Japan, and some European countries. It is currently only available in Cuba. In October 2015 Serbian Institute of Virology Torlak signed memorandum for a full medical treatment of 30 patients that will be part of a clinical study. CimaVax is relatively cheap to produce and store, and has low toxicity. Side effects of the vaccine appear to be mild, and include chills, fever, and feeling sick.